二甲双胍联合生活方式干预对肥胖老年人躯体功能的影响(DEMFOS 随机对照试验)
DEMFOS 随机安慰剂对照试验纳入 114 名 65-85 岁、BMI≥30 kg/m2 的肥胖老年人,比较强化生活方式加安慰剂、强化生活方式加二甲双胍、健康生活方式加二甲双胍三组 6 个月时改良躯体功能测试评分的变化。结果显示强化生活方式加二甲双胍组优于健康生活方式加二甲双胍组,但与强化生活方式加安慰剂组无差异,提示在强化生活方式干预基础上二甲双胍未带来额外躯体功能获益。
要点
- 在强化生活方式干预基础上加用二甲双胍未额外改善肥胖老年人的躯体功能。
- 6 个月时强化生活方式加二甲双胍组躯体功能测试改善优于健康生活方式加二甲双胍组。
- 研究支持优先采用生活方式策略改善该人群的功能结局。
核心结论
- 在肥胖老年人接受强化生活方式干预时,二甲双胍未提供额外的躯体功能改善。
- 结果支持优先采用生活方式策略改善该人群的功能结局。
研究设计与样本
- DEMFOS 为随机、安慰剂对照试验,在美国休斯敦 Michael E DeBakey 退伍军人医学中心与 Baylor College of Medicine 开展。
- 纳入 65-85 岁、BMI≥30 kg/m2 的肥胖老年人,随机分为强化生活方式加安慰剂、强化生活方式加二甲双胍、健康生活方式加二甲双胍三组。
- 主要结局为 6 个月时改良躯体功能测试评分变化,主要分析按意向性治疗进行。
主要发现
- 严重不良事件不常见,且未归因于研究干预。
关键数值与推荐
- 主要结局为 6 个月时改良躯体功能测试评分变化。
临床怎么用
- 对肥胖老年人的躯体功能改善,应优先实施强化生活方式干预(体重管理与运动训练)。
- 不宜仅以改善躯体功能为目的在强化生活方式干预基础上常规加用二甲双胍。
局限性
- 样本以男性为主(101/114,89%),外推至女性老年人群需谨慎。
- 研究在单一退伍军人医学中心开展,结论的普遍适用性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Obesity in older adults is associated with functional decline and increased risk of disability. Lifestyle interventions improve physical function, but the role of metformin as an adjunct to lifestyle intervention in this population remains unclear. In this randomised clinical trial, we evaluated whether metformin enhances the effects of an intensive lifestyle intervention on physical function in older adults with obesity. METHODS: The Diet and Exercise plus Metformin to Treat Frailty in Obese Seniors (DEMFOS) trial (ClinicalTrials.gov: NCT04221750 [completed]) was a randomised, placebo-controlled trial conducted at the Michael E DeBakey Veterans Affairs Medical Center and Baylor College of Medicine (Houston, TX, USA). Older adults (aged 65-85 years) with obesity (BMI ≥30 kg/m2) were randomly assigned to intensive lifestyle intervention (weight-management and exercise training) plus placebo, intensive lifestyle intervention plus metformin, or healthy lifestyle (diet education) plus metformin groups. The primary outcome was change in the modified physical performance test score at 6 months. The primary analysis was by intention-to-treat. FINDINGS: Of 221 participants assessed for eligibility between March 30, 2021, and Dec 12, 2024, 114 were included in this study (mean age 72·8 years [SD 5·2]; 101 [89%] men and 13 [11%] women). 64 (56%) participants were White, 50 (44%) were Black, and 15 (13%) were Hispanic or Latino. Changes in physical performance test differed between groups (group-by-time interaction p<0·0001). At 6 months, physical performance test improvement was greater in the intensive lifestyle plus metformin group than in the healthy lifestyle plus metformin group (mean difference 2·5 points, 95% CI 1·2-3·8; p=0·0002), whereas there was no difference between the intensive lifestyle plus metformin and intensive lifestyle plus placebo groups (0·1 points, -1·2 to 1·4; p=0·92). Serious adverse events were infrequent and not attributed to the study interventions. INTERPRETATION: Our findings suggest that in older adults with obesity undergoing intensive lifestyle intervention, metformin does not provide additional improvement in physical function. These results support prioritising lifestyle-based strategies to improve functional outcomes in this population. FUNDING: US Department of Veterans Affairs.
引用
- Nava MLD, Viola V, Aguilar M, et al. Metformin added to lifestyle intervention for physical function in older adults with obesity (DEMFOS trial): a randomised controlled trial. Lancet Healthy Longev. 2026. PMID: 42532077. doi:10.1016/j.lanhl.2026.100883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。